HomeCompareADOIF vs PLD

ADOIF vs PLD: Dividend Comparison 2026

ADOIF yields 22.55% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.82M in total portfolio value· pulled ahead in Year 6
10 years
ADOIF
ADOIF
● Live price
22.55%
Share price
$8.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$85.3K
Annual income
$8,766.27
Full ADOIF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — ADOIF vs PLD

📍 PLD pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADOIFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADOIF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADOIF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADOIF
Annual income on $10K today (after 15% tax)
$1,916.36/yr
After 10yr DRIP, annual income (after tax)
$7,451.33/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,030,665.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADOIF + PLD for your $10,000?

ADOIF: 50%PLD: 50%
100% PLD50/50100% ADOIF
Portfolio after 10yr
$3.00M
Annual income
$2,379,745.73/yr
Blended yield
79.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ADOIF
Analyst Ratings
1
Buy
Consensus: Buy
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADOIF buys
0
PLD buys
0
No recent congressional trades found for ADOIF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADOIFPLD
Forward yield22.55%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$85.3K$5.91M
Annual income after 10y$8,766.27$4,750,725.19
Total dividends collected$51.4K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ADOIF vs PLD ($10,000, DRIP)

YearADOIF PortfolioADOIF Income/yrPLD PortfolioPLD Income/yrGap
1$12,955$2,254.54$11,241$540.96+$1.7KADOIF
2$16,591$2,729.58$13,019$991.13+$3.6KADOIF
3$21,019$3,267.09$15,801$1,870.97+$5.2KADOIF
4$26,359$3,868.35$20,609$3,701.21+$5.8KADOIF
5$32,738$4,533.70$29,919$7,867.97+$2.8KADOIF
6← crossover$40,292$5,262.47$50,631$18,617.74$10.3KPLD
7$49,166$6,053.05$105,528$51,352.20$56.4KPLD
8$59,510$6,902.90$287,364$174,449.42$227.9KPLD
9$71,484$7,808.68$1,081,760$774,280.77$1.01MPLD
10$85,255$8,766.27$5,908,209$4,750,725.19$5.82MPLD

ADOIF vs PLD: Complete Analysis 2026

ADOIFStock

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

Full ADOIF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ADOIF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADOIF vs SCHDADOIF vs JEPIADOIF vs OADOIF vs KOADOIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.